Corvus Pharmaceuticals, Inc. (CRVS) SEC Filings — 2025
14 SEC filings for Corvus Pharmaceuticals, Inc. (CRVS) in 2025.
Filings
- Corvus Pharmaceuticals, Inc. 8-K Filing — 8-K · Nov 4, 2025
- Corvus Narrows Losses, Boosts Marketable Securities Amid Going Concern Doubts — 10-Q · Nov 4, 2025
- Corvus Pharmaceuticals Reports Leadership and Compensation Changes — 8-K · Oct 2, 2025
- Corvus Pharmaceuticals Files 8-K on Financials — 8-K · Aug 7, 2025
- Corvus Narrows Q2 Loss Amid R&D Cuts, Seeks Mupadolimab Partner — 10-Q · Aug 7, 2025
- Corvus Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025
- Corvus Pharmaceuticals Files 8-K — 8-K · Jun 4, 2025
- Corvus Pharmaceuticals Files 8-K — 8-K · May 8, 2025
- Corvus Pharma Q1 2025: Assets $68.17M, Liabilities $67.90M — 10-Q · May 8, 2025
- Corvus Pharma Files Proxy Statement — DEFA14A · Apr 25, 2025
- Corvus Pharma Announces Executive and Board Changes — 8-K · Apr 9, 2025
- Corvus Pharmaceuticals Files 8-K on Financials — 8-K · Mar 25, 2025
- Corvus Pharmaceuticals Files 2024 10-K — 10-K · Mar 25, 2025
- Corvus Pharmaceuticals Files 8-K — 8-K · Jan 13, 2025